Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines...
Published in: | Revista do Instituto de Medicina Tropical de São Paulo |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Universidade de São Paulo (USP)
2018
|
Subjects: | |
Online Access: | https://doi.org/10.1590/s1678-9946201860029 https://doaj.org/article/9d02ad81afa6421089067f67acde4271 |
id |
ftdoajarticles:oai:doaj.org/article:9d02ad81afa6421089067f67acde4271 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:9d02ad81afa6421089067f67acde4271 2024-09-09T19:27:31+00:00 Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir Lenyta Oliveira Gomes Marina Rodrigues Teixeira Júnior André da Rosa Alberi Adolfo Feltrin João Paulo V. Rodrigues Mariane D’Avila Vecchi Jane Meire M. Carneiro Lúcia de Araújo C. B. Noblat Silvana Gama F. Chachá Ana de Lourdes C. Martinelli Leonardo Regis L. Pereira Marysabel Pinto T. Silveira Carine Raquel Blatt Mareni Rocha Farias 2018-06-01T00:00:00Z https://doi.org/10.1590/s1678-9946201860029 https://doaj.org/article/9d02ad81afa6421089067f67acde4271 EN eng Universidade de São Paulo (USP) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000217&lng=en&tlng=en https://doaj.org/toc/1678-9946 1678-9946 doi:10.1590/s1678-9946201860029 https://doaj.org/article/9d02ad81afa6421089067f67acde4271 Revista do Instituto de Medicina Tropical de São Paulo, Vol 60, Iss 0 (2018) Chronic hepatitis C treatment Protease inhibitors High cost medicines Real life studies Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2018 ftdoajarticles https://doi.org/10.1590/s1678-9946201860029 2024-08-05T17:49:30Z ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in therapy and their high cost require a discussion about the consequences for patients and for the health system of the early incorporation of new therapies. The article presents a qualitative analysis of the incorporation process of both medications in Brazil and the results of a multicenter study that included patients treated with BOC or TVR between January 2011 and December 2015 in five Brazilian cities. The study included 855 patients (BOC: n=247) and (TVR: n=608). The document analysis showed that CONITEC’s decision to incorporate BOC and TVR was based on results of phase III clinical trials that compared sustained virologic response (SVR) rates of patients treated with BOC and TVR with rates of those that received placebo. However, these studies included a low percentage of cirrhotic patients. The SVR rates observed in this multicenter study were worse than clinical trials pointed out (BOC: 45.6%; TVR: 51.8%), but similar to those achieved with previously adopted therapies. The discontinuation rate due to adverse events was (BOC: 15.4%; TVR: 12.7%). Based on these unsatisfactory results, the study brings a discussion that goes beyond the therapy outcomes, exploring the incorporation of these high-cost medicines and the related decision-making process, contributing to future decisions in medicine policies and in the treatment of chronic hepatitis C. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Revista do Instituto de Medicina Tropical de São Paulo 60 0 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Chronic hepatitis C treatment Protease inhibitors High cost medicines Real life studies Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Chronic hepatitis C treatment Protease inhibitors High cost medicines Real life studies Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Lenyta Oliveira Gomes Marina Rodrigues Teixeira Júnior André da Rosa Alberi Adolfo Feltrin João Paulo V. Rodrigues Mariane D’Avila Vecchi Jane Meire M. Carneiro Lúcia de Araújo C. B. Noblat Silvana Gama F. Chachá Ana de Lourdes C. Martinelli Leonardo Regis L. Pereira Marysabel Pinto T. Silveira Carine Raquel Blatt Mareni Rocha Farias Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
topic_facet |
Chronic hepatitis C treatment Protease inhibitors High cost medicines Real life studies Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
ABSTRACT In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in therapy and their high cost require a discussion about the consequences for patients and for the health system of the early incorporation of new therapies. The article presents a qualitative analysis of the incorporation process of both medications in Brazil and the results of a multicenter study that included patients treated with BOC or TVR between January 2011 and December 2015 in five Brazilian cities. The study included 855 patients (BOC: n=247) and (TVR: n=608). The document analysis showed that CONITEC’s decision to incorporate BOC and TVR was based on results of phase III clinical trials that compared sustained virologic response (SVR) rates of patients treated with BOC and TVR with rates of those that received placebo. However, these studies included a low percentage of cirrhotic patients. The SVR rates observed in this multicenter study were worse than clinical trials pointed out (BOC: 45.6%; TVR: 51.8%), but similar to those achieved with previously adopted therapies. The discontinuation rate due to adverse events was (BOC: 15.4%; TVR: 12.7%). Based on these unsatisfactory results, the study brings a discussion that goes beyond the therapy outcomes, exploring the incorporation of these high-cost medicines and the related decision-making process, contributing to future decisions in medicine policies and in the treatment of chronic hepatitis C. |
format |
Article in Journal/Newspaper |
author |
Lenyta Oliveira Gomes Marina Rodrigues Teixeira Júnior André da Rosa Alberi Adolfo Feltrin João Paulo V. Rodrigues Mariane D’Avila Vecchi Jane Meire M. Carneiro Lúcia de Araújo C. B. Noblat Silvana Gama F. Chachá Ana de Lourdes C. Martinelli Leonardo Regis L. Pereira Marysabel Pinto T. Silveira Carine Raquel Blatt Mareni Rocha Farias |
author_facet |
Lenyta Oliveira Gomes Marina Rodrigues Teixeira Júnior André da Rosa Alberi Adolfo Feltrin João Paulo V. Rodrigues Mariane D’Avila Vecchi Jane Meire M. Carneiro Lúcia de Araújo C. B. Noblat Silvana Gama F. Chachá Ana de Lourdes C. Martinelli Leonardo Regis L. Pereira Marysabel Pinto T. Silveira Carine Raquel Blatt Mareni Rocha Farias |
author_sort |
Lenyta Oliveira Gomes |
title |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
title_short |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
title_full |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
title_fullStr |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
title_full_unstemmed |
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir |
title_sort |
hepatitis c in brazil: lessons learned with boceprevir and telaprevir |
publisher |
Universidade de São Paulo (USP) |
publishDate |
2018 |
url |
https://doi.org/10.1590/s1678-9946201860029 https://doaj.org/article/9d02ad81afa6421089067f67acde4271 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista do Instituto de Medicina Tropical de São Paulo, Vol 60, Iss 0 (2018) |
op_relation |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000217&lng=en&tlng=en https://doaj.org/toc/1678-9946 1678-9946 doi:10.1590/s1678-9946201860029 https://doaj.org/article/9d02ad81afa6421089067f67acde4271 |
op_doi |
https://doi.org/10.1590/s1678-9946201860029 |
container_title |
Revista do Instituto de Medicina Tropical de São Paulo |
container_volume |
60 |
container_issue |
0 |
_version_ |
1809896946570100736 |